BIOPHARM FORWARD ApS: Financial statements 2024
CVR: 32438784
Source: annual report 2024, Danish Business Authority
26/08/2023 – 25/08/2024
BIOPHARM FORWARD ApS (CVR 32438784) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 1,056,751 and a net result of DKK 385,061 compared with DKK -107,301 the year before. That is an increase of 92.2% compared with the year before. Equity in the 2024 report amounted to DKK 1,632,655. The solvency ratio was 79.3%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,056,751
- Profit/Loss
- DKK 385,061
- Equity
- DKK 1,632,655
- Total Assets
- DKK 2,057,633
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 1.1 mio. | 385 t. | 1.6 mio. | 1 |
| 2023 | - | 550 t. | -107 t. | 1.4 mio. | 1 |
| 2022 | - | 584 t. | 156 t. | 1.6 mio. | 1 |
| 2021 | - | 928 t. | 1.5 mio. | 1.6 mio. | 1 |
| 2020 | - | 182 t. | 146 t. | 209 t. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
BIOPHARM FORWARD ApS has published its annual report for 2023. Gross profit came to DKK 549,847, and the net result was DKK -107,301.
About BIOPHARM FORWARD ApS
BIOPHARM FORWARD ApS is a Danish company of the type Anpartsselskab based in Espergærde, founded in 2009. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Jonas Hink. The company is owned by Jonas Hink. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK 997,234 and a net result of DKK 243,660 compared with DKK 385,061 the year before. Equity in the 2025 report amounted to DKK 1,741,315.